Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516738 | 0.87 | EPHX2 (0.50) | P2RX7EPHX2 | |
| SCHEMBL4517546 | 0.86 | EPHX2 (0.51) | P2RX7ALDH1A1EPHX2L3MBTL1MAPT | |
| SCHEMBL14365321 | 0.86 | EPHX2 (0.51) | P2RX7ALDH1A1EPHX2L3MBTL1MAPT | |
| SCHEMBL2993666 | 0.85 | HSD11B1 (0.40) | P2RX7MEN1KMT2AEPHX2 | |
| SCHEMBL2993670 | 0.85 | HSD11B1 (0.40) | P2RX7MEN1KMT2AEPHX2 | |
| SCHEMBL2995839 | 0.83 | P2RX7 (0.44) | P2RX7EPHX2 | |
| SCHEMBL2996038 | 0.83 | P2RX7 (0.44) | P2RX7EPHX2 | |
| SCHEMBL2990514 | 0.83 | P2RX7 (0.44) | P2RX7EPHX2 | |
| SCHEMBL4515016 | 0.83 | HSD11B1 (0.43) | P2RX7SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL2992277 | 0.81 | P2RX7 (0.43) | P2RX7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | P2RX7 3946/4885SMN1; SMN2 4487/4885MEN1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.